ADARx Pharmaceuticals Announces Dosing of First
Cohort in Phase 1 Clinical Study of ADX-324

January 20, 2023 2:30 PM Eastern Standard Time
SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage
biotechnology company developing RNA-targeting therapeutics, today announced the
dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of
hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful,
rapid, and potentially life-threatening swelling attacks.
“We are very excited to be advancing our first candidate that utilizes our proprietary
PLR™ delivery platform and SPE™ technology into the clinic,” said Zhen Li,
President and Chief Executive Officer. “ADX-324 represents an innovative and
differentiated approach for the treatment of HAE.”
“Dosing of our first participants in this trial is a major milestone for ADARx; in addition
to its potential best-in-class efficacy, our pre-clinical studies in non-human primates
have confirmed the likelihood for a bi-annual, and possibly annual, low volume
subcutaneous dose regimen for ADX-324,” said Feriandas Greblikas, Vice President
of Clinical Development.
ADX-324 is a short-interfering RNA (siRNA) designed to reduce the production of
PKK, a protein critical to the etiology of HAE. The study is being conducted in
Australia as a randomized, placebo-controlled, double-blind, single ascending dose
trial in healthy volunteers with an expansion cohort in patients with HAE. The primary
objective of the study is to evaluate the safety and tolerability of ADX-324 when
administered by subcutaneous injection.
More information can be found here:
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary
Angioedema Patients – Full Text View – ClinicalTrials.gov

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology
company committed to turning cutting-edge science into life-saving therapeutics.
ADARx is developing a proprietary RNA targeting platform, including oligonucleotides
for inhibition, degradation, and editing, together with novel oligonucleotide delivery
technologies including its PLR™ (“Preeminent Liver RNA”) platform and SPE™
(“Sequence Specific Platform Enhancement”) technology. ADARx has a growing
pipeline of RNA targeting therapeutics for treating diseases across a range of
therapeutic areas including genetic, cardiometabolic, complement-mediated and
central nervous system diseases.

Contacts

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic

January 20, 2023 9:26 AM Eastern Standard Time

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company’s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital all participating in the financing. In conjunction with this financing, Dr. Lorence Kim of Ascenta Capital has joined the Company’s Board of Directors.

“siRNA has evolved from a spectacular platform technology into a new class of medicines. ADARx represents a next generation of unique insights into oligonucleotide chemistry, pushing siRNA’s frontier with efficient translation of ADARx science into potential medicines addressing large unmet medical needs across therapeutic areas,” said Dr. Lorence Kim of Ascenta Capital. “My co-founder, Evan Rachlin, and I formed Ascenta Capital to help companies like ADARx grow into and realize their potential. We are thrilled to partner with Dr. Li and her team as they move the portfolio into the first of many clinical studies of important new RNA medicines.”

The proceeds from the Series B-1 financing will be used to advance ADARx’s proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. The timing of this financing coincides with ADARx’s lead product candidate, ADX-324, for the treatment of hereditary angioedema beginning its phase I clinical trial.

“This is an exciting time for ADARx as we make the transition to a clinical stage biotechnology company,” said Dr. Zhen Li, President, and Chief Executive Officer of ADARx. “This round of funding with the support of our investor syndicate allows us to pursue our near-term objectives of progressing our first three product candidates into the clinic while continuing our discovery and development efforts across multiple therapeutic areas.”

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.

About Ascenta Capital

Ascenta Capital is a biotech-focused late-stage venture fund, co-founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim. The fund is focused on concentrated investments in companies developing portfolios of therapeutics based on innovative platform technologies. For more information about Ascenta Capital, visit www.ascentacap.com.

Contacts

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer

January 09, 2023 6:23 AM Eastern Standard Time

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer.

“I am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,” said Dr. Zhen Li, President, and Chief Executive officer of ADARx. “As ADARx continues to grow, Robert will help to drive the evolving research and development needs of our organization. Robert’s experience in the discovery and development of RNA therapeutics across multiple therapeutic areas supports our goal of turning cutting-edge science into life-saving therapeutics.”

Dr. MacLeod joins ADARx as ADX-324 for the treatment of hereditary angioedema is currently enrolling healthy volunteers for its phase I clinical trial. ADARx has two additional drug candidates set to enter clinical trials in 2023 and an extensive pipeline to follow. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, most recently as Vice President and Franchise Head of Oncology. He has led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of 15 novel investigational therapeutics and over 100 high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada, and his Ph.D. in Cancer Epigenetics from McGill University.

“It’s an exciting time in RNA therapeutics and I believe ADARx will be a leader in this space with its broad approach to discovering and developing novel therapies,” said Dr. MacLeod. “I look forward to contributing to the impressive advances in the ADARx platforms that have already generated its first clinical stage program and a deep discovery pipeline in the Company’s still short history.”

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.

Contacts

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Further Expands Leadership
Team, Appointing Feriandas Greblikas, M.D. as VP of
Clinical Development

October 18, 2022 9:46 AM Eastern Daylight Time

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the further expansion of their leadership team and clinical development capabilities through the appointment of Feriandas Greblikas, M.D. as Vice President of Clinical Development.

“We are very excited to have Feriandas join the ADARx team,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “With his wealth of experience in drug development and clinical execution, he will make significant contributions to ADARx’s strategy, and operational effectiveness as we continue to advance programs to the clinic.”

Dr. Greblikas joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials later this year and two additional drug candidates are expected to enter clinical trials next year.

Dr. Greblikas is an established physician-scientist with more than 10 years of extensive experience in drug development, medical oversight, clinical trial planning and execution. Prior to joining ADARx, Dr. Greblikas served as a Senior Medical Director at Travere Therapeutics, in which he contributed to the development of pegtibatinase and fosmetpantothenate programs. Prior positions include Medical Director at BioMarin, Baxter and Biogen, and significant contributions to approved drugs Palynziq®, Adynovate® and Eloctate®. Dr. Greblikas received his M.D. in pediatrics from the Vilnius University. Dr. Greblikas also holds an Economics diploma from the International Business School of Vilnius University.

“I am delighted to join the passionate team at ADARx and be part of a shared commitment of bringing safe and effective treatments to patients with unmet needs,” said Dr. Greblikas. “The ADARx pipeline presents diverse options for first-in-class and best-in-class drugs to realize this commitment.”

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are entering clinical stage.

Contacts

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Expands Leadership Team, Appointing Christopher Prentiss as CFO

September 28, 2022 10:20 AM Eastern Daylight Time

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer.

“I am delighted to welcome Chris to ADARx with his extensive financial experience in the pharmaceutical industry,” said Dr. Zhen Li, President, and Chief Executive officer of ADARx. “As ADARx continues to grow, our evolving leadership structure reflects the expanding development needs of our organization as we enter clinical trials. Chris’s experience in the development and launch of pharmaceutical products directly supports our goal of turning cutting-edge science into life-saving therapeutics.”

Mr. Prentiss joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials at the end of the year. ADARx has two additional drug candidates set to enter clinical trials next year and an extensive pipeline to follow.

Mr. Prentiss has over 20 years of experience in senior financial positions with public companies in the life sciences industry. Mr. Prentiss most recently served as Chief Financial Officer of Adamas Pharmaceuticals, Inc. where he was responsible for leading the finance, investor relations, and information technology functions. During his tenure, Adamas received approval for and commercialized GOCOVRI® until the Company’s acquisition by Supernus Pharmaceuticals, Inc. Previous roles include senior finance positions at biopharmaceutical companies including Adamas Pharmaceuticals, Inc., InterMune, Inc., Dynavax Technologies Corporation, and MannKind Corporation. Prior to joining the biopharmaceutical field, Mr. Prentiss was at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor’s of Science degree in Accounting from Loyola Marymount University and a MBA from Indiana University’s Kelley School of Business. Mr. Prentiss is a CPA licensed in California.

“I am excited to join the ADARx team at this pivotal point as the company transitions into a clinical stage organization,” said Mr. Prentiss. “I am impressed with ADARx’s drug platform, and I look forward to contributing my skills and experience to ADARx and the continued growth and development of its impressive pipeline.”

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are at IND-enabling stage.

Contacts

ADARx
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

San Diego, California, June 7, 2022 – ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.

“I am delighted to welcome Andrew to the ADARx team, as his wealth of experience in the biotech industry will greatly enhance our capabilities,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Andrew has deep expertise across key aspects of development from preclinical studies to NDA submission and his leadership offers great benefit to the company as we continue to expand our pipeline and advance programs to the clinic.”

Dr. Seacat has over 20 years of experience in nonclinical drug development, toxicology, and drug safety evaluation and, in his new role, will lead all GLP and non-GLP toxicology studies for our RNA-targeting therapeutics. Dr. Seacat was most recently Senior Director, Pharmacology and Toxicology at Zogenix (a wholly owned subsidiary of UCB S.A.) where he led authoring of all non-clinical sections of an NDA. Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals and Senior Director, Preclinical Development at La Jolla Pharmaceuticals. He also had increasing roles of responsibility in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Medical Department. Dr. Seacat received a Doctorate in Biochemical Molecular Toxicology and completed a Postdoctoral Fellowship at Johns Hopkins University. Dr Seacat was also Diplomate of the American Board of Toxicology (DABT_2001-2015).

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are at IND-enabling stage.

Contacts

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@www.adarx.com

ADARx Pharmaceuticals Expands Leadership Team

San Diego, California, January 25, 2022 – ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher D. Claeboe, Ph.D., MBA as VP, CMC and Manufacturing. 

“I am excited to welcome Chris to the ADARx team at this important time in our company,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Chris’ manufacturing expertise will prove to be an invaluable asset as we move the company into clinical development and beyond.”  

Dr. Claeboe’s role at ADARx will focus on developing our RNA therapeutics, establishing a manufacturing network, leading drug substance and drug product production, and oversight of CMC regulatory. Dr. Claeboe brings to ADARx extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization. He was most recently Executive Director at ChemoCentryx, Inc., in which he contributed significantly to the CMC development activities for their recently approved drug Tavneos™. Prior positions include Director at Codexis, Inc. Dr. Claeboe received a Ph.D. in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship at Indiana University. Dr. Claeboe also earned his MBA from Indiana University’s Kelley School of Business.

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases. 

ADARx Contact
Roselle Corbaley

(877) 232-7974

ir@www.adarx.com

ADARx Raises $75 Million to Advance Growing Pipeline

Proceeds to advance and expand pipeline of RNA targeting therapeutics.

SAN DIEGO, CA, September 8, 2021 – ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline.  The Series B was co-led by SR One Capital Management and OrbiMed Advisors.  Sirona Capital joined this financing as well as existing investors OrbiMed Advisors and Lilly Asia Ventures.

“The ADARx team is laser-focused on efficiently translating their insights around RNA biology into novel medicines to benefit patients.  The team has made tremendous progress in the advancement of its unique, multi-faceted RNA platform in the short time since the Company’s launch and we look forward to helping build the pipeline with this financing,” said Simeon George, M.D., CEO of SR One.

“OrbiMed is pleased to continue to back Zhen Li and her team in the creation of an exciting oligonucleotide-based drug company, which is creating new treatment modalities,” said Carl Gordon, Ph.D., CFA, Founding Partner and Co-Head of Global Private Equity at OrbiMed Advisors.

The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery. The proceeds will also be used to transition ADARx’s growing pipeline of research phase products into the clinic including initiation of a Phase 1 clinical trial for ADARx’s lead program.

“We are excited that our RNA base editing technology could give rise to a significant pipeline of highly effective therapeutics,” said Zhen Li, Ph.D., President and Chief Executive Officer of ADARx. “In parallel, we are using our delivery technology to pursue additional RNA targeting approaches within a wide range of therapeutic areas including genetic, cardiometabolic and central nervous system diseases. We are thrilled with the support from our new investors and greatly appreciate the confidence of our existing investors in our technology and our team.”

About ADARx
ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics.  ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.  ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.     

About SR One
SR One Capital Management is a trans-Atlantic venture capital firm that partners with entrepreneurs to build companies with a mission to address significant unmet needs in medicine and healthcare.  The firm, which was spun out of GSK in 2020, has a history of investing in the biotech ecosystem since 1985, and has a presence in the San Francisco Bay Area, the Philadelphia area and in London, UK.  For more information about SR One, visit www.srone.com.

About OrbiMed

OrbiMed has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 100 distinguished scientific, medical, investment and other professionals manages over $19 billion across public and private company investments worldwide. From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives.

ADARx Contact

Roselle Corbaley

(877) 232-7974

ir@www.adarx.com